In addition to this, we have compulsory policies and procedures for the handling of nanomaterials (Use and Handling of Nanomaterials), the use of animal testing in research and development (Use, Care and Welfare of Laboratory Animals), and our engagement in promoting access to health (Charter on Access to Medicines in Developing Countries) in developing health care systems.
Extensive information for patients
We believe that worldwide access to medicinal product information is one of the keys to improving health care and treatment for patients. We recognize the important role that patient organizations play in providing support to patients, as well as in disseminating information to patients and their caregivers. We therefore support the educational work of various patient organizations with donations and funding. We explicitly endeavor to exert no influence or control over the information that the organizations communicate to their members. For comprehensive transparency, we publish our donations to European patient organizations on our website and update the information annually.
In order to promote advances in the field of medicine, we sponsor research and advanced medical education globally, reflecting our commitment to science, education and patient care. For example, our biopharmaceuticals business supports outstanding extramural research projects through its Grant for Fertility Innovation and its Grant for Multiple Sclerosis Innovation which are both awarded annually and available to researchers and clinicians worldwide. Similar annual Grants for Innovation were launched in 2013 in Oncology and Growth Disorders and the first awards in these fields will be granted in 2014. Through contributions to multiple Medical Education providers, we support the development and delivery of independent advanced medical training for scientists, physicians, nurses, pharmacists, and other health care professionals.
Furthermore, to support the health care system, we make donations to institutions, organizations and associations that include, for example, medical science professional associations, hospitals and university clinics. These donations take the form of financial contributions and equipment donations, as well as one-time monetary payments and benefits in kind. This support reflects our Values and allows research institutes and related institutions to more easily do their work, which ultimately serves the common good. The contributions are not intended to influence decisions regarding treatment, prescriptions or purchasing. In the following table, Merck KGaA, Darmstadt, Germany has published the donations made within Germany that exceed EUR 10,000 per person/per year. The entries are updated on an annual basis.